Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2011, Article ID 616080, 3 pages
http://dx.doi.org/10.1155/2011/616080
Case Report

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma

1Division of Hematology, Oncology, Department of Medicine, Columbia University, NY 10027, USA
2Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA
3Oncology Unit, 3rd Department of Medicine, Athens University School of Medicine, Building Z, Sotiria General Hospital, Mesogion 152, 115 27 Athens, Greece

Received 24 January 2011; Revised 28 March 2011; Accepted 7 April 2011

Academic Editor: Fabio Farinati

Copyright © 2011 Muhammad W. Saif et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [3 citations]

The following is the list of published articles that have cited the current article.

  • Yves-Paul Vandewynckel, Anja Geerts, Xavier Verhelst, and Hans Van Vlierberghe, “Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma,” Clinical Case Reports, vol. 2, no. 1, pp. 4–6, 2013. View at Publisher · View at Google Scholar
  • Fatma Maraiki, and Ali Aljubran, “Carotid and brachiocephalic arteries stenosis with long term use of sorafenib,” Hematology/ Oncology and Stem Cell Therapy, vol. 7, no. 1, pp. 53–55, 2014. View at Publisher · View at Google Scholar
  • Joerg Herrmann, Eric H. Yang, Cezar A. Iliescu, Mehmet Cilingiroglu, Konstantinos Charitakis, Abdul Hakeem, Konstantinos Toutouzas, Massoud A. Leesar, Cindy L. Grines, and Konstantinos Marmagkiolis, “Vascular Toxicities of Cancer Therapies The Old and the New - An Evolving Avenue,” Circulation, vol. 133, no. 13, pp. 1272–1289, 2016. View at Publisher · View at Google Scholar